101 related articles for article (PubMed ID: 38761360)
1. Correction to: Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities.
Kewan T; Stahl M; Bewersdorf JP; Zeidan AM
Curr Hematol Malig Rep; 2024 Jun; 19(3):151. PubMed ID: 38761360
[No Abstract] [Full Text] [Related]
2. Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults.
Zandberg DP; Huang TY; Ke X; Baer MR; Gore SD; Smith SW; Davidoff AJ
Haematologica; 2013 Apr; 98(4):584-90. PubMed ID: 23144192
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Platzbecker U; Della Porta MG; Santini V; Zeidan AM; Komrokji RS; Shortt J; Valcarcel D; Jonasova A; Dimicoli-Salazar S; Tiong IS; Lin CC; Li J; Zhang J; Giuseppi AC; Kreitz S; Pozharskaya V; Keeperman KL; Rose S; Shetty JK; Hayati S; Vodala S; Prebet T; Degulys A; Paolini S; Cluzeau T; Fenaux P; Garcia-Manero G
Lancet; 2023 Jul; 402(10399):373-385. PubMed ID: 37311468
[TBL] [Abstract][Full Text] [Related]
4. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
[TBL] [Abstract][Full Text] [Related]
5. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.
Stein EM; Fathi AT; DiNardo CD; Pollyea DA; Roboz GJ; Collins R; Sekeres MA; Stone RM; Attar EC; Frattini MG; Tosolini A; Xu Q; See WL; MacBeth KJ; de Botton S; Tallman MS; Kantarjian HM
Lancet Haematol; 2020 Apr; 7(4):e309-e319. PubMed ID: 32145771
[TBL] [Abstract][Full Text] [Related]
6. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome.
Deschler B; Ihorst G; Platzbecker U; Germing U; März E; de Figuerido M; Fritzsche K; Haas P; Salih HR; Giagounidis A; Selleslag D; Labar B; de Witte T; Wijermans P; Lübbert M
Haematologica; 2013 Feb; 98(2):208-16. PubMed ID: 22875615
[TBL] [Abstract][Full Text] [Related]
7. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.
Komrokji R; Garcia-Manero G; Ades L; Prebet T; Steensma DP; Jurcic JG; Sekeres MA; Berdeja J; Savona MR; Beyne-Rauzy O; Stamatoullas A; DeZern AE; Delaunay J; Borthakur G; Rifkin R; Boyd TE; Laadem A; Vo B; Zhang J; Puccio-Pick M; Attie KM; Fenaux P; List AF
Lancet Haematol; 2018 Feb; 5(2):e63-e72. PubMed ID: 29331635
[TBL] [Abstract][Full Text] [Related]
8. Current and Future Treatment Options for Myelodysplastic Syndromes: More Than Hypomethylating Agents and Lenalidomide?
Sockel K; Platzbecker U
Drugs; 2018 Dec; 78(18):1873-1885. PubMed ID: 30467725
[TBL] [Abstract][Full Text] [Related]
9. Flow Cytometric Assessment of Myelodysplastic Syndromes/Neoplasms.
Chen X; Johansson U; Cherian S
Clin Lab Med; 2023 Dec; 43(4):521-547. PubMed ID: 37865501
[TBL] [Abstract][Full Text] [Related]
10. Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies.
Kelaidi C; Stamatoullas A; Beyne-Rauzy O; Raffoux E; Quesnel B; Guerci A; Dreyfus F; Brechignac S; Berthou C; Prebet T; Hicheri Y; Hacini M; Delaunay J; Gourin MP; Camo JM; Zerazhi H; Taksin AL; Legros L; Choufi B; Fenaux P;
Haematologica; 2010 Jun; 95(6):892-9. PubMed ID: 20015890
[TBL] [Abstract][Full Text] [Related]
11. [Management of myelodysplastic syndromes in 2019: An update].
Comont T; Delavigne K; Cougoul P; Bertoli S; Delabesse E; Fenaux P; Beyne-Rauzy O
Rev Med Interne; 2019 Sep; 40(9):581-589. PubMed ID: 31054780
[TBL] [Abstract][Full Text] [Related]
12. Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial.
Taylor J; Mi X; Penson AV; Paffenholz SV; Alvarez K; Sigler A; Chung SS; Rampal RK; Park JH; Stein EM; Tallman MS; Sen F; Gönen M; Abdel-Wahab O; Klimek VM
Lancet Haematol; 2020 Aug; 7(8):e566-e574. PubMed ID: 32735836
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems.
Fu B; Jaso JM; Sargent RL; Goswami M; Verstovsek S; Medeiros LJ; Wang SA
Mod Pathol; 2014 May; 27(5):681-9. PubMed ID: 24186132
[TBL] [Abstract][Full Text] [Related]
14. Blood and Marrow Transplant Clinical Trials Network Study 1102 heralds a new era in hematopoietic cell transplantation in high-risk myelodysplastic syndromes: Challenges and opportunities in implementation.
Warlick ED; Ustun C; Andreescu A; Bonagura AF; Brunner A; Chandra AB; Foran JM; Juckett MB; Kindwall-Keller TL; Klimek VM; Pease DF; Steensma DP; Waldman BM; Horowitz MM; Burns LJ; Khera N
Cancer; 2021 Dec; 127(23):4339-4347. PubMed ID: 34375439
[TBL] [Abstract][Full Text] [Related]
15. Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?
Hochman MJ; DeZern AE
Lancet Haematol; 2022 Jul; 9(7):e523-e534. PubMed ID: 35772431
[TBL] [Abstract][Full Text] [Related]
16. Clinical and genetic predictors of prognosis in myelodysplastic syndromes.
Bejar R
Haematologica; 2014 Jun; 99(6):956-64. PubMed ID: 24881041
[TBL] [Abstract][Full Text] [Related]
17. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.
Garcia-Manero G; Roboz G; Walsh K; Kantarjian H; Ritchie E; Kropf P; O'Connell C; Tibes R; Lunin S; Rosenblat T; Yee K; Stock W; Griffiths E; Mace J; Podoltsev N; Berdeja J; Jabbour E; Issa JJ; Hao Y; Keer HN; Azab M; Savona MR
Lancet Haematol; 2019 Jun; 6(6):e317-e327. PubMed ID: 31060979
[TBL] [Abstract][Full Text] [Related]
18. A novel RUNX1 mutation with ANKRD26 dysregulation is related to thrombocytopenia in a sporadic form of myelodysplastic syndrome.
Ferrari S; Regazzo D; Omenetto E; Scaroni C; Semenzato G; Fabris F; Vianello F
Aging Clin Exp Res; 2021 Jul; 33(7):1987-1992. PubMed ID: 32944898
[TBL] [Abstract][Full Text] [Related]
19. Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes.
Cluzeau T; McGraw KL; Irvine B; Masala E; Ades L; Basiorka AA; Maciejewski J; Auberger P; Wei S; Fenaux P; Santini V; List A
Haematologica; 2017 Dec; 102(12):2015-2020. PubMed ID: 28983059
[TBL] [Abstract][Full Text] [Related]
20. Current status of phase 3 clinical trials in high-risk myelodysplastic syndromes: pitfalls and recommendations.
Garcia-Manero G
Lancet Haematol; 2023 Jan; 10(1):e71-e78. PubMed ID: 36215988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
